Organization
University of Texas Health San Antonio MD Anderson Cancer Center
1 abstract
Abstract
MyTACTIC: Afficacy and safety of atezolizumab (atezo) + chemotherapy (chemo) in patients (pts) with advanced unresectable/metastatic solid tumors with high tumor mutational burden (TMB-H) or high microsatellite instability (MSI-H)/deficient mismatch repair (dMMR).Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, OneOncology, Inc., New York Cancer and Blood Specialists,